Annovis Bio ( (ANVS) ) has provided an announcement.
On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with the NYSE’s continued listing standards due to its average market capitalization and stockholders’ equity falling below $50 million. The company plans to submit a compliance plan within 45 days, which the NYSE will review to determine if Annovis can meet the standards within an 18-month period. The notice does not affect the company’s business operations or its reporting obligations, and its stock will continue to be traded with a ‘.BC’ designation until compliance is regained.
More about Annovis Bio
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a late-stage clinical drug platform company focused on pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company targets multiple neurotoxic proteins to restore brain function and improve the quality of life for patients.
YTD Price Performance: -63.80%
Average Trading Volume: 510,712
Technical Sentiment Signal: Buy
Current Market Cap: $36.05M
For an in-depth examination of ANVS stock, go to TipRanks’ Stock Analysis page.